Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Hepatobiliary Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm
Hepatobiliary Neoplasm

Cancer Family

Hepatobiliary Neoplasm

CI-CAN-00000198Explore in graph →

Non-malignant1,187 active trials17 approved drugs42 evidence items

NCIt: C8614

Overview
Statistics
Survival
Genomics32
Variants & evidence42
Drugs25
Trials5262
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (128)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 101–125 of 128 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma.
· NPJ Precis Oncol · 2019 · PMID 31453370 · validated civic_curation pubmed
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
· JCO Precis Oncol · 2024 · PMID 38603650 · validated civic_curation pubmed
Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.
· Oncotarget · 2016 · PMID 26701727 · validated civic_curation pubmed
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
· Cancer Discov · 2016 · PMID 27231123 · validated civic_curation pubmed
Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment.
· Cancer Sci · 2010 · PMID 20088962 · validated civic_curation pubmed
Jusakul et al. Cancer Discov 2017
· 2017 · PMID 28667006 · validated cbioportal_study pubmed
Jiao et al. Nat Genet 2013
· 2013 · PMID 24185509 · validated cbioportal_study pubmed

Showing 101–125 of 128 publications

← Previous
1
…
4
5
6
Next →

Lowery et al. Clin Cancer Res 2018

· 2018 · PMID 29848569 · validated cbioportal_study pubmed

Chan-on et al. Nat Genet 2013

· 2013 · PMID 24185513 · validated cbioportal_study pubmed

Ong et al. Nat Genet 2012

· 2012 · PMID 22561520 · validated cbioportal_study pubmed

Raja et al, Cancer 2018

· 2018 · PMID 30427539 · validated cbioportal_study pubmed

Nicolas A et al. Clin Cancer Res 2022

· 2022 · PMID 36228155 · validated cbioportal_study pubmed

Maolan Li et al. Nat Genet 2014

· 2014 · PMID 24997986 · validated cbioportal_study pubmed

Chen L et al. Nature 2024

· 2024 · PMID 38355797 · validated cbioportal_study pubmed

Schulze et al. Nat Genet 2013

· 2013 · PMID 25822088 · validated cbioportal_study pubmed

Darren et al. JCO Precis Oncol 2023

· 2023 · PMID 37769223 · validated cbioportal_study pubmed

Charlotte Ng et al. Nat Commun. 2022

· 2022 · PMID 35508466 · validated cbioportal_study pubmed

Song, Yi et al. Clin Cancer Res 2024

· 2024 · PMID 38864854 · validated cbioportal_study pubmed

Zheng et al. PLOS One 2018

· 2018 · PMID 30052636 · validated cbioportal_study pubmed

Harding et al. Clin Cancer Res 2018

· 2018 · PMID 30373752 · validated cbioportal_study pubmed

Xue et al. Cancer Cell 2019

· 2019 · PMID 31130341 · validated cbioportal_study pubmed

Sia et al. Nature Commun 2015

· 2015 · PMID 25608663 · validated cbioportal_study pubmed

Boerner et al. Hepatology 2021

· 2021 · PMID 33765338 · validated cbioportal_study pubmed

Jolissaint et al. Clin Cancer Res 2021

· 2021 · PMID 33963001 · validated cbioportal_study pubmed

Shanshan et al. Nat Commun 2014

· 2014 · PMID 25526346 · validated cbioportal_study pubmed